This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Zacks Analyst Blog Highlights: Intel, Exxon Mobil, Johnson & Johnson, JPMorgan and Microsoft
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Intel, Exxon Mobil, Johnson & Johnson, JPMorgan and Microsoft
TESARO (TSRO) Q3 Earnings Beat, Revenues Miss, Shares Up
by Zacks Equity Research
TESARO (TSRO) beats estimates for earnings in the third quarter but misses the same on revenues. Zejula sales maintain momentum.
AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings top estimates while revenues fall short. Revenues increase year over year on strong sales growth of Humira, Imbruvica and Mavyret.
VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.
5 of the Best Blue-Chip Stocks to Ride the Dow Rally
by Tirthankar Chakraborty
The Dow made a fantastic comeback, courtesy of Trump indicating a potential headway in U.S.-China trade relations.
Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
The Pharmaceuticals Industry Stock Outlook: A Steady Path Ahead
by Kinjel Shah
Pipeline success, cost cutting, share buybacks, product launches, increased M&A and collaboration activities are the factors that drives the large-cap pharma industry.
Pfizer (PFE) Beats on Q3 Earnings, Meets Sales, Narrows View
by Zacks Equity Research
Pfizer's (PFE) third-quarter earnings beat estimates while sales match the same. The company narrows its full-year sales and profit targets
The Zacks Analyst Blog Highlights: Johnson & Johnson, UnitedHealth, AT&T and Intel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, UnitedHealth, AT&T and Intel
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $137.55, moving +0.42% from the previous trading session.
Top Stock Picks for the Week of October 29th
by Panel Of Zacks Experts
Our experts take a look at two good defensive plays.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
Top Analyst Reports for Johnson & Johnson, UnitedHealth, AT&T & Intel
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including Johnson & Johnson (JNJ), UnitedHealth (UNH), AT&T (T) and Intel (INTC).
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
J&J Intends to Buy Residual Stake in Japanese Skincare Firm
by Zacks Equity Research
Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Bristol-Myers Declines, FDA Delays Review of Opdivo for NSCLC
by Zacks Equity Research
The FDA defers decision by three months regarding the sBLA of Bristol-Myers' (BMY) Opdivo in combination with Yervoy for the treatment of metastatic first-line NSCLC.
Biogen (BIIB) Q3 Earnings & Sales Beat, Spinraza Shines
by Zacks Equity Research
Biogen beat estimates for both earnings and sales in the third quarter. Its newest drug Spinraza performs well in the quarter.
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
by Zacks Equity Research
Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Johnson & Johnson (JNJ) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $138.68, marking a -0.27% move from the previous day.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Netflix, Microsoft, Amazon and Alphabet
Quiet Friday Session Caps Another Volatile Week in the Markets
by David Borun
Earnings and Geopolitical events contribute to another wild ride
Upcoming Tech Earnings to Watch: MSFT, AMZN, GOOGL
by Ryan McQueeney
More major tech reports will begin pouring in next week, and Wall Street will be hoping for strength from the sector's leaders. Here's a close look at a few of the major tech earnings reports due out in the coming days.